Atlas Trials

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Clinical trial NCT05856526 · TERMINATED

Trial details

NCT number
NCT05856526
Sponsor
Boehringer Ingelheim
Status
TERMINATED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Netherton Syndrome
Start date
2023-06-12
Primary completion
2025-01-13
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.